U.S. markets close in 14 minutes
  • S&P 500

    4,160.57
    -24.90 (-0.59%)
     
  • Dow 30

    34,067.14
    -133.53 (-0.39%)
     
  • Nasdaq

    13,897.85
    -154.49 (-1.10%)
     
  • Russell 2000

    2,230.23
    -32.44 (-1.43%)
     
  • Crude Oil

    63.37
    +0.24 (+0.38%)
     
  • Gold

    1,770.90
    -9.30 (-0.52%)
     
  • Silver

    25.88
    -0.23 (-0.88%)
     
  • EUR/USD

    1.2041
    +0.0061 (+0.51%)
     
  • 10-Yr Bond

    1.6010
    +0.0280 (+1.78%)
     
  • GBP/USD

    1.3989
    +0.0149 (+1.08%)
     
  • USD/JPY

    108.1570
    -0.6260 (-0.58%)
     
  • BTC-USD

    55,734.09
    +419.58 (+0.76%)
     
  • CMC Crypto 200

    1,261.11
    -37.85 (-2.91%)
     
  • FTSE 100

    7,000.08
    -19.45 (-0.28%)
     
  • Nikkei 225

    29,685.37
    +2.00 (+0.01%)
     

Amgen submits U.S. application to sell cholesterol-fighting drug

Aug 28 (Reuters) - Amgen Inc said it submitted an application to the U.S. Food and Drug Administration to market its cholesterol-lowering drug, evolocumab.

The injectable drug works by blocking PCSK9, a naturally occurring protein that keeps "bad" LDL cholesterol levels elevated in the bloodstream.

Other drugmakers, including Pfizer Inc, and a partnership between Regeneron Inc and Sanofi SA , are racing with Amgen to market potentially lucrative anti-PCSK9 antibodies.

(Reporting by Natalie Grover in Bangalore; Editing by Maju Samuel)